York spinout Cizzle Biotechnology has undertaken a reverse merger with Bould Opportunities to list on the London Stock Exchange.
Cizzle Biotechnology, a UK-based developer of a blood test to detect lung cancer that was spun out of University of York, has completed a reverse merger with blank cheque company Bould Opportunities and listed on the London Stock Exchange (LSE).
The £21m ($29m) deal marks the first time that a York spinout has listed on LSE. The combined business will operate as Cizzle Biotechnology Holdings.
Founded in 2004 as M&R 971, Cizzle Biotechnology has created a blood test…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
